Biocon's margin squeeze may get worse before it gets better
Published on 15/09/2025 10:35 AM
Biocon's margin squeeze may get worse before it gets betterBengaluru-based Biocon's new plant in the US is aimed at capturing some of the business from the US government under President Donald Trump who is focussed on bringing the cost of medicines down. However, it's going to cost Biocon some more of its relatively small margin.By Sriram Iyer September 15, 2025, 10:35:21 AM IST (Updated)3 Min ReadWith its new plant operational in New Jersey, US, Bengaluru-based Bioconis hoping to get some of the business from President Donald Trump's push for cheaper drugs and local manufacturing. It's likely to cost the company some of its profit margin.Continue Reading with CNBC-TV18 Access MembershipPriority Access and Networking: CNBC-TV18's flagship events Interaction with CNBC-TV18's journalists Webinars & LIVE Q&As with India Inc. Leaders Exclusive CNBC-TV18 studio & newsroom tours Premium business insights, expert opinions & analysis Curated lifestyle privileges & offers